SHORT MINI-FUTURE - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 11:14:45 04/07/2024 pm IST | ||
| 2.34 EUR | -4.49% |
|
| Current month | +24.47% | ||
| 1 month | -11.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 2.34 | -4.49% |
| 03/24/03 | 2.45 | +22.50% |
| 02/24/02 | 2 | +14.94% |
| 01/24/01 | 1.74 | -7.45% |
| 28/24/28 | 1.88 | +2.73% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 11:14 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1XAK |
| ISIN | DE000VD1XAK8 |
| Date issued | 08/03/2024 |
| Strike | 1,143 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.07 € |
|---|---|
| Lowest since issue | 1.57 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Certificates
- Certificat
